Skip to main content
Caplight Logo









Vedanta Biosciences

Vedanta Biosciences

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.vedantabio.com/

Last Round

Early Funding

Aug 6, 2026

Total Funding Raised

$317.5M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Vedanta Biosciences is a biotechnology company that develops microbiome-based oral therapies for the treatment of immune-mediated and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

microbiome therapeuticsdefined bacterial consortialive biotherapeutic productsLBPgut microbiotaClostridioides difficile infectionC. diffinflammatory bowel diseaseIBDfecal microbiota transplant alternativeFMT alternativebiopharmaceutical R&Ddrug discovery platformclinical-stage biotechmultidrug-resistant organismMDRO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vedanta Biosciences Comparables

Compare Vedanta Biosciences with similar companies based on industry and business-model similarity.

Vedanta Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Seres Therapeutics Inc
81%
MarvelBiome Inc.
81%
EnteroBiotix
80%

Vedanta Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingAug 6, 2026
GrantApr 30, 2024
VC RoundApr 25, 2023
Series DJul 21, 2021
GrantSep 30, 2020
Grant
Dec 5, 2019

Key People

Founding team and executive leadership

Daniel Couto

Chief Operating Officer

Executive Team

Vedanta Biosciences Investors

Notable investors and investment history

Vedanta Biosciences investors
InvestorRounds
SV InvestmentSeries C Extension, Series C
AMR Action FundVC Round, Early Funding
SymBiosis Capital ManagementSeries D, Series C Extension, Series C
Invesco Ltd.Series C, Series B
Administration for Strategic Preparedness and ResponseGrant
Salica InvestmentsVC Round
Korea Investment PartnersVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 6, 2026

    $40M round led by BNP Paribas Asset Management and AMR Action Fund.

  • Apr 1, 2026

    Lead asset VE303 enters Phase 3 trial for C. difficile infection.

Vedanta Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vedanta Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vedanta Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range84
Year Founded2010
Last FundingAug 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?